Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.

doi:10.1182/blood-2013-03-492181

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.

Blood - 12 Sept 2013

Oaks Joshua J, Santhanam Ramasamy, Walker Christopher J, Roof Steve, Harb Jason G, Ferenchak Greg, Eisfeld Ann-Kathrin, Van Brocklyn James R, Briesewitz Roger, Saddoughi Sahar A, Nagata Kyosuke, Bittman Robert, Caligiuri Michael A, Abdel-Wahab Omar, Levine Ross, Arlinghaus Ralph B, Quintas-Cardama Alfonso, Goldman John M, Apperley Jane, Reid Alistair, Milojkovic Dragana, Ziolo Mark T, Marcucci Guido, Ogretmen Besim, Neviani Paolo, Perrotti Danilo

Abstract excerpt

FTY720 (Fingolimod, Gilenya) is a sphingosine analog used as an immunosuppressant in multiple sclerosis patients. FTY720 is also a potent protein phosphatase 2A (PP2A)-activating drug (PAD). PP2A is a tumor suppressor found inactivated in different types of cancer. We show here that PP2A is inactive in polycythemia vera (PV) and other myeloproliferative neoplasms characterized by the expression of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Transformed

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Histone Chaperones

Share to Leukemia

Share to Mice, SCID

Share to Oncogene Proteins

Share to Protein Kinase C

Share to Protein Phosphatase 2

Share to Sphingosine

Source

Open in PubMed Open full text

Identifiers

PMID: 23926298
DOI: 10.1182/blood-2013-03-492181
PMCID: PMC3772499

Genes

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.PMID 23926298Read ↗

Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2ASemantic proximity Read ↗

JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.Semantic proximity Read ↗

Targeting myeloproliferative neoplasms with JAK inhibitors.Semantic proximity Read ↗

Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.Semantic proximity Read ↗

PITPβ Drives JAK2 V617F-Mediated Myeloproliferative Neoplasms by Promoting PtdIns(3,4)P <sub>₂</sub> -Dependent AKT HyperactivationSemantic proximity Read ↗

Role of SHP2 phosphatase in KIT-induced transformation: identification of SHP2 as a druggable target in diseases involving oncogenic KIT.Semantic proximity Read ↗

Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera.Semantic proximity Read ↗

PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemiaSemantic proximity Read ↗

JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective.Semantic proximity Read ↗

CDK6 coordinates JAK2V617F mutant MPN via NF-κB and apoptotic networksSemantic proximity Read ↗

The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod.Semantic proximity Read ↗

Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617FSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.